Jun 8, 2026 | Client Report, Drug costs, Employer costs, Health care costs, Outpatient care, Rx Costs
Milliman’s 2026 Medical Index projects a 7.9% increase in per-person health care costs for employer-sponsored plans — the highest annual rise in more than a decade, outside of pandemic years. From 2021 to 2025, Milliman’s national medical & pharmacy trend averaged...
May 26, 2026 | Benefits preservation, Drug costs, MedBen Rx, Rx Costs, Specialty Drugs
A recent Pharmaceutical Strategies Group analysis shows managing specialty drug costs is now the top priority for employer health plans —surpassing total cost of care. MedBen Rx’s Benefit Preservation Program addresses this by reducing specialty drug spend by an...
May 4, 2026 | Biosimilars, Cost Savings, Drug costs, MedBen Rx, Rebates, Rx Costs, Savings
Specialty drugs account for more than half of total drug spend and are often the largest cost driver for employer pharmacy plans. A recent BenefitPRO article points to biosimilars as a practical solution — and for MedBen Rx clients, the effect is already clear, with...
Mar 23, 2026 | Clinical guidelines, Drug advertising, MedBen Rx, Rx Costs
Heavy direct-to-consumer advertising of high-cost medications is fueling patient demand and placing added pressure on physicians to prescribe the drugs that patients recognize — even when lower-cost alternatives may be just as, or more, effective. The scale of this...
Feb 23, 2026 | Biosimilars, Cost Savings, Drug costs, MedBen Rx, Rx Costs, Specialty Drugs
Specialty medications continue to dominate pharmacy spend, now accounting for 52% of all U.S. pharmaceutical sales, according to a recent report from the Healthcare Distribution Alliance. With costs often reaching tens — or even hundreds — of thousands of dollars per...
Dec 29, 2025 | MedBen Rx, Pharmacy, Pharmacy Benefits Manager (PBM), Rebates, Rx Costs, Transparency
While the major PBMs still dominate the market, their grip is loosening. A recent Pulse of the Purchaser survey found that the percentage of employers contracted with one of the Big 3 dropped from 72% in 2024 to 61% by late 2025, as more organizations shifted toward...
